Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2, has spread globally, and no proven treatments are available. Convalescent plasma …

Context.—Early diagnosis of gram-negative bloodstream infections, prompt identification of
the infecting organism, and appropriate antibiotic therapy improve patient care outcomes and …

Background An intervention for Gram-negative bloodstream infections that integrated mass
spectrometry technology for rapid diagnosis with antimicrobial stewardship oversight …

Rapid microbiologic tests provide opportunities for antimicrobial stewardship programs to
improve antimicrobial use and clinical and economic outcomes. Standard techniques for …

Background We compared the efficacy of the antiviral agent, remdesivir, versus standard-of-care
treatment in adults with severe coronavirus disease 2019 (COVID-19) using data from a …

Ceftaroline is the first member of a novel class of cephalosporins approved for use in the
United States. Although prior studies have identified eight ceftaroline-resistant methicillin-…

OBJECTIVETo assess the impact of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight
(MALDI-TOF) mass spectrometry for rapid pathogen identification directly from early-…

Background Remdesivir is approved by the US Food and Drug Administration for the treatment
of patients hospitalized with coronavirus disease 2019 (COVID-19) and has been shown …

Background COVID-19 disease, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), has spread globally, and no proven treatments are available. Convalescent …

Delayed administration of active anti-infective therapy is associated with increased rates of
adverse events, mortality, and costs among sepsis patients. Inherent limitations of …